Hina M. Porcelli

News
Selpercatinib Demonstrates Safety, Efficacy in RET-Altered NSCLC and Thyroid Cancer Regardless of Prior Treatment Status
06/28/2022
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic review and meta-analysis show that selpercatinib is a safe and effective option for patients with RET-altered NSCLC and thyroid cancer, regardless of previous therapies or RET alteration type.
Findings from a systematic...
06/28/2022
Oncology
Conference Coverage
First-Line Ibrutinib Combined With Bendamustine-Rituximab and Rituximab Maintenance Improves PFS in MCL
06/04/2022
Ibrutinib combined with bendamustine plus rituximab and rituximab maintenance significantly improved PFS vs standard chemoimmunotherapy in patients aged ≥65 years with untreated MCL, according to findings from the phase 3 SHINE trial.
Ibrutinib combined with bendamustine plus rituximab and rituximab maintenance significantly improved PFS vs standard chemoimmunotherapy in patients aged ≥65 years with untreated MCL, according to findings from the phase 3 SHINE trial.
Ibrutinib combined with...
06/04/2022
Oncology
Conference Coverage
Brentuximab Vedotin Improves EFS in Pediatric Patients With High–Risk Hodgkin Lymphoma
06/04/2022
Brentuximab vedotin added to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVE-PC) improves EFS over AVE-PC plus bleomycin in pediatric patients with previously untreated, high–risk Hodgkin lymphoma.
Brentuximab vedotin added to doxorubicin, vincristine, etoposide, prednisone and cyclophosphamide (AVE-PC) improves EFS over AVE-PC plus bleomycin in pediatric patients with previously untreated, high–risk Hodgkin lymphoma.
Brentuximab vedotin added to...
06/04/2022
Oncology
Conference Coverage
Experts Observe Durable Antitumor Activity With Selpercatinib for RET Fusion-Positive Solid Tumors
06/28/2022
Selpercatinib continues to demonstrate robust antitumor activity in patients with varying RET fusion-positive solid tumor cancers, according to an update from the LIBRETTO-001 trial presented at the 2022 ASCO Annual Meeting.
Selpercatinib continues to demonstrate robust antitumor activity in patients with varying RET fusion-positive solid tumor cancers, according to an update from the LIBRETTO-001 trial presented at the 2022 ASCO Annual Meeting.
Selpercatinib continues to...
06/28/2022
Oncology
Conference Insider
Venetoclax–Azacitidine Improves OS Over Azacitidine Alone in Treatment-Naïve Patients With tMN, A-MDS/MPNs
06/23/2021
According to data presented at ASCO 2021, venetoclax plus azacitidine improved survival over azacitidine alone in treatment-naïve patients with tMN and antecedent MDS or MPNs.
According to data presented at ASCO 2021, venetoclax plus azacitidine improved survival over azacitidine alone in treatment-naïve patients with tMN and antecedent MDS or MPNs.
According to data presented at...
06/23/2021
Oncology
Conference Insider
Second-Line Triplet Combo Shows Promise in Patients With HER2+ Advanced GI/GEJ Cancer
06/02/2021
According to Sun Young Rha, MD, PhD, et al, second-line trastuzumab plus ramucirumab and paclitaxel showed promising activity and manageable safety in a study of patients with HER2+ GI/GEJ cancer.
According to Sun Young Rha, MD, PhD, et al, second-line trastuzumab plus ramucirumab and paclitaxel showed promising activity and manageable safety in a study of patients with HER2+ GI/GEJ cancer.
According to Sun Young Rha, MD,...
06/02/2021
Oncology
News
FDA Approves Dostarlimab-gxly for Adults With dMMR Endometrial Cancer
04/22/2021
The FDA has approved dostarlimab-gxly for the treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed during or after a platinum-containing therapy.
The FDA has approved dostarlimab-gxly for the treatment of adults with dMMR recurrent or advanced endometrial cancer that progressed during or after a platinum-containing therapy.
The FDA has approved...
04/22/2021
Oncology
Conference Coverage
First-Line Brentuximab Vedotin Plus Chemotherapy Improves OS in Classical Hodgkin Lymphoma: ECHELON-1
06/04/2022
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a 41% reduction in the risk of death over doxorubicin, bleomycin, vinblastine, and dacarbazine for previously untreated classical Hodgkin lymphoma, according to an...
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a 41% reduction in the risk of death over doxorubicin, bleomycin, vinblastine, and dacarbazine for previously untreated classical Hodgkin lymphoma, according to an...
Brentuximab vedotin plus...
06/04/2022
Oncology
Conference Coverage
Trabectedin Does Not Improve Survival vs Standard Chemotherapy for BRCA–Positive Ovarian Cancer
06/06/2022
Single-agent trabectedin was not associated with improved survival outcomes compared to standard chemotherapy for patients with BRCA–positive ovarian cancer, according to results from a phase 3 trial.
Single-agent trabectedin was not associated with improved survival outcomes compared to standard chemotherapy for patients with BRCA–positive ovarian cancer, according to results from a phase 3 trial.
Single-agent trabectedin was not...
06/06/2022
Oncology
Conference Coverage
First-Line Rucaparib Maintenance Following Chemotherapy Provides Significant Benefit in Ovarian Cancer
06/06/2022
Rucaparib monotherapy provides significant benefit over placebo as first-line maintenance treatment following platinum-based chemotherapy in ovarian cancer, according to results from the ATHENA-MONO trial.
Rucaparib monotherapy provides significant benefit over placebo as first-line maintenance treatment following platinum-based chemotherapy in ovarian cancer, according to results from the ATHENA-MONO trial.
Rucaparib monotherapy provides...
06/06/2022
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
SAWC Spring
April 30 ⁠–⁠ May 4
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use